Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities must designate a U.S. Agent to facilitate communication with the FDA. While there is no standard, fixed fee for...
When evaluating 'Person Responsible for Regulatory Compliance (PRRC) as a Service' providers, how can manufacturers move beyond a simple comparison of annual fees to conduct a comprehensive cost-value...
When a medical device manufacturer, particularly a small or non-EU based entity, decides to outsource the role of the Person Responsible for Regulatory Compliance (PRRC) as permitted under the EU MDR,...
When a medical device manufacturer decides to outsource the Person Responsible for Regulatory Compliance (PRRC) role required under European regulations, what specific, practical framework can be used...
As global regulations and scientific understanding of certain chemical substances evolve, how should medical device sponsors approach FDA premarket submissions for devices containing materials that fa...
With increasing regulatory scrutiny on per- and polyfluoroalkyl substances (PFAS) under REACH, and with significant ECHA developments anticipated around 2026, non-EU manufacturers face a critical chal...
For non-EEA manufacturers preparing for the forthcoming EU REACH restrictions on Per- and Polyfluoroalkyl Substances (PFAS), selecting a qualified Only Representative (OR) is a crucial step, particula...
For non-EU medical device manufacturers, how might the announced 2026 changes to France's VAT and import agent requirements affect logistical operations and overall EU market strategy? While CE markin...
For sponsors of a novel Software as a Medical Device (SaMD) that appears to lack a clear predicate device, what is the systematic process for determining the appropriate US regulatory pathway, specifi...
For a connected medical device, such as a wireless patient monitor or a software-as-a-medical-device (SaMD) application, how should a sponsor structure the cybersecurity documentation within a premark...
How should a medical device manufacturer, particularly one without a physical establishment in the EU or UK, develop a comprehensive strategy for selecting a WEEE/EPR authorized representative or comp...
For in vitro diagnostic (IVD) devices, what key factors differentiate a moderate-risk Class II device, which is often subject to special controls, from a high-risk Class III device that requires a Pre...
For manufacturers of electrical and electronic medical devices, navigating environmental compliance regulations like the Waste from Electrical and Electronic Equipment (WEEE) Directive and Extended Pr...
For medical device manufacturers, particularly small to medium-sized enterprises (SMEs) or those based outside the European Union, engaging a "PRRC as a Service" provider is a common strategy to fulfi...
When evaluating external "PRRC as a Service" providers for 2025 budgets, medical device manufacturers find that pricing is not standardized and can vary significantly. Instead of a fixed cost, the fee...
When evaluating 'Person Responsible for Regulatory Compliance (PRRC) as a Service' providers under the EU MDR, how can a medical device manufacturer move beyond comparing simple monthly retainers to a...
Given the European Union's advancing restrictions on per- and polyfluoroalkyl substances (PFAS) under REACH, what is the comprehensive due diligence process for a non-EU medical device manufacturer to...
For non-EU medical device manufacturers, selecting an EU Authorized Representative (AR) is a critical requirement for compliance with the Medical Device Regulation (MDR) and In Vitro Diagnostic Regula...
When a company plans to import chemical substances or mixtures into the European Union that are subject to REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals), they often appo...
When developing a prescription software device intended to analyze ophthalmic images for diagnostic purposes, how can sponsors effectively navigate the regulatory requirements associated with the "ret...